Biomimetics for treating biofilm-embedded infections

Award Information
Agency:
Department of Defense
Branch
Army
Amount:
$749,860.00
Award Year:
2010
Program:
STTR
Phase:
Phase II
Contract:
W911NF-10-C-0111
Award Id:
n/a
Agency Tracking Number:
A2-4098
Solicitation Year:
2009
Solicitation Topic Code:
A09A-T004
Solicitation Number:
2009.A
Small Business Information
170 N. Radnor-Chester Road, Suite 300, Radnor, PA, 19087-5279
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
621470033
Principal Investigator:
RichardScott
VP Research
(484) 598-2336
rscott@polymedix.com
Business Contact:
DawnEringis
Director, Scientific Affairs
(484) 598-2334
deringis@polymedix.com
Research Institute:
University of Massachusetts Amherst
Carol Sprague
Office of Grants and Contract
70 Butterfield Terrace
Amherst, MA, 01003-9242
(413) 545-0698

Abstract
Multi-drug resistant (MDR) biofilms are one of the most difficult bacterial infections to treat. Current antibiotics are increasingly unable to cure these infections; underscoring the need to develop new antibiotics that operate through novel mechanisms which overcome the biofilm environment. PolyMedix has discovered a novel class of antibiotics, SMAMPS (small mimics of antimicrobial peptides), that work through a mechanism which appears to evade resistance development and is not depended on bacterial growth. One SMAMP is currently in human clinical trials to treat nosocomial infections, including methicillin-resistant S. aureus. During the Phase I STTR, potently active lead compounds were identified against pathogens associated with biofilm-embedded infections. Resistance to other antibiotics did not influence susceptibility to the PMX mimetics. Rapid killing kinetics and a low risk for the development of resistance are hallmark features of PMX mimetics and underscore their potential as novel antimicrobial agents suitable for further development for treatment of infections complicated by biofilm formation. This Phase II STTR aims to identify SMAMPs that are potently active in in vitro and in vivo biofilm infection models and possess pharmaceutical qualities suitable for further development.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government